Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe

EBioMedicine

Volumn 22, Issue , 2017, Pages 164-172

  Launay, Odile ^a,f,g,h   Lewis, David J M ^b   Anemona, Alessandra ^c   Loulergue, Pierre ^a,f,g   Leahy, Jo ^b   Sciré, Antonella Silvia ^c   Maugard, Anaïs ^a,f,g   Marchetti, Elisa ^c   Zancan, Stefano ^c,i   Huo, Zhiming ^b   Rondini, Simona ^c   Marhaba, Rachid ^d   Finco, Oretta ^c   Martin, Laura B ^c   Auerbach, Jochen ^c   Cohen, Daniel ^e   Saul, Allan ^c   Gerke, Christiane ^c,j   Podda, Audino ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c GSK   (Italy)

^d GSK Vaccines GmbH   (Germany)

^e TEL AVIV UNIVERSITY   (Israel)

^f INSERM   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

ⁱ FONDAZIONE TELETHON   (Italy)

^j INSTITUT PASTEUR   (France)

more..

Author keywords

Clinical study; GMMA; Shigella sonnei; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; HLA B27 ANTIGEN; SHIGELLA VACCINE;

ADULT; AGGLUTINATION TEST; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; CELLULAR IMMUNITY; CHILL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MOUTH TEMPERATURE; MYALGIA; NEUTROPENIA; PAIN SEVERITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; RISK ASSESSMENT; SHIGELLA SONNEI; SHIGELLOSIS; SINGLE BLIND PROCEDURE; SKIN INDURATION; VACCINE IMMUNOGENICITY; CLINICAL TRIAL; COMPARATIVE STUDY; EUROPE; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; NORMAL HUMAN; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADULT; EUROPE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; SHIGELLA SONNEI; SHIGELLA VACCINES; YOUNG ADULT;

EID: 85025461951     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2017.07.013     Document Type: Article

References (34)

1. Bardhan, P., Faruque, A.S., Naheed, A., Sack, D.A., Decrease in shigellosis-related deaths without Shigella spp.-specific interventions, Asia. Emerg. Infect. Dis. 16:11 (2010), 1718–1723.
2. Bowen, A., Hurd, J., Hoover, C., et al. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014–February 2015. MMWR Morb. Mortal. Wkly Rep. 64:12 (2015), 318–320.
3. Camacho, A.I., Irache, J.M., Gamazo, C., Recent progress towards development of a Shigella vaccine. Expert Rev. Vaccines 12:1 (2013), 43–55.
4. Cohen, D., Block, C., Green, M.S., Lowell, G., Ofek, I., Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J. Clin. Microbiol. 27:1 (1989), 162–167.
5. Cohen, D., Green, M.S., Block, C., Slepon, R., Ofek, I., Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J. Clin. Microbiol. 29:2 (1991), 386–389.
6. Cohen, D., Ashkenazi, S., Green, M.S., et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349:9046 (1997), 155–159.
7. Ekdahl, K., Andersson, Y., The epidemiology of travel-associated shigellosis—regional risks, seasonality and serogroups. J. Inf. Secur. 51:3 (2005), 222–229.
8. Ferreccio, C., Prado, V., Ojeda, A., et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol. 134:6 (1991), 614–627.
9. Fries, L.F., Montemarano, A.D., Mallett, C.P., Taylor, D.N., Hale, T.L., Lowell, G.H., Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69:7 (2001), 4545–4553.
10. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:10053 (2016), 1459–1544.
11. Gerke, C., Colucci, A.M., Giannelli, C., et al. Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB. PLoS One, 10(8), 2015, e0134478.
12. Gu, B., Cao, Y., Pan, S., et al. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009. Int. J. Antimicrob. Agents 40:1 (2012), 9–17.
13. Herrington, D.A., Van de Verg, L., Formal, S.B., et al. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8:4 (1990), 353–357.
14. Kaminski, R.W., Oaks, E.V., Inactivated and subunit vaccines to prevent shigellosis. Expert Rev. Vaccines 8:12 (2009), 1693–1704.
15. Klontz, K.C., Singh, N., Treatment of drug-resistant Shigella infections. Expert Rev. Anti-Infect. Ther. 13:1 (2015), 69–80.
16. Kotloff, K.L., Nataro, J.P., Losonsky, G.A., et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 13:16 (1995), 1488–1494.
17. Kotloff, K.L., Winickoff, J.P., Ivanoff, B., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. 77:8 (1999), 651–666.
18. Kotloff, K.L., Nataro, J.P., Blackwelder, W.C., et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382:9888 (2013), 209–222.
19. Kubler-Kielb, J., Schneerson, R., Mocca, C., Vinogradov, E., The elucidation of the structure of the core part of the LPS from Plesiomonas shigelloides serotype O17 expressing O-polysaccharide chain identical to the Shigella sonnei O-chain. Carbohydr. Res. 343:18 (2008), 3123–3127.
20. Levine, M.M., Kotloff, K.L., Barry, E.M., Pasetti, M.F., Sztein, M.B., Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 5:7 (2007), 540–553.
21. Lindsay, B., Ochieng, J.B., Ikumapayi, U.N., et al. Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries. J. Clin. Microbiol. 51:6 (2013), 1740–1746.
22. Liu, J., Kabir, F., Manneh, J., et al. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. Lancet Infect. Dis. 14:8 (2014), 716–724.
23. Livio, S., Strockbine, N.A., Panchalingam, S., et al. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin. Infect. Dis. 59:7 (2014), 933–941.
24. Lozano, R., Naghavi, M., Foreman, K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2095–2128.
25. Maggiore, L., Yu, L., Omasits, U., et al. Quantitative proteomic analysis of Shigella flexneri and Shigella sonnei generalized modules for membrane antigens (GMMA) reveals highly pure preparations. Int. J. Med. Microbiol. 306:2 (2016), 99–108.
26. Mani, S., Wierzba, T., Walker, R.I., Status of vaccine research and development for Shigella. Vaccine 34:26 (2016), 2887–2894.
27. Muturi-Kioi, V., Lewis, D., Launay, O., et al. Neutropenia as an adverse event following vaccination: results from randomized clinical trials in healthy adults and systematic review. PLoS One, 11(8), 2016, e0157385.
28. Passwell, J.H., Ashkenzi, S., Banet-Levi, Y., et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 28:10 (2010), 2231–2235.
29. Slifka, M.K., Ahmed, R., Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay. J. Immunol. Methods 199:1 (1996), 37–46.
30. Toneatto, D., Ismaili, S., Ypma, E., Vienken, K., Oster, P., Dull, P., The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum. Vaccin. 7:6 (2011), 646–653.
31. Wahid, R., Simon, J.K., Picking, W.L., Kotloff, K.L., Levine, M.M., Sztein, M.B., Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. Clin. Immunol. 148:1 (2013), 35–43.
32. Zaman, M., Chandrudu, S., Toth, I., Strategies for intranasal delivery of vaccines. Drug Deliv. Transl. Res. 3:1 (2013), 100–109.
33. Zehrung, D., Jarrahian, C., Wales, A., Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine 31:34 (2013), 3392–3395.
34. Zychlinsky, A., Perdomo, J.J., Sansonetti, P.J., Molecular and cellular mechanisms of tissue invasion by Shigella flexneri. Ann. N. Y. Acad. Sci. 730 (1994), 197–208.